Close

Needham & Company Downgrades Sarepta Therapeutic (SRPT) to Hold

November 12, 2013 12:46 PM EST Send to a Friend
Needham & Company downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold after the FDA issued a major set back ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login